Coexisting depressive symptoms do not limit the benefits of chronic neuromodulation: A study of over 200 patients by Killinger, Kim A. et al.
Au
tho
r M
an
us
cri
pt
This article is protected by copyright. All rights reserved. 
Original Clinical Article 
COEXISTING DEPRESSIVE SYMPTOMS DO NOT LIMIT THE BENEFITS OF 
CHRONIC NEUROMODULATION: A STUDY OF OVER 200 PATIENTS 1 
 
Kim A. Killinger 0000-0001-9228-8758 0000-0001-9228-87581,2, Jonathan Fergus2, Luke 
Edwards1,  Judith A. Boura1, 2, Jamie Bartley1,2, Priyanka Gupta3, Janice Tomakowsky1, 
Jason Gilleran1, 2, Kenneth M. Peters1, 2  
1Beaumont Health, Royal Oak, MI  
2Oakland University William Beaumont School of Medicine, Rochester, MI 
3 University of Michigan, Department of Urology, Ann Arbor, MI 
 
Corresponding Author: 
Kim A. Killinger  
Beaumont, Royal Oak 
3535 West 13 Mile Road Ste. 438 
Royal Oak, MI 48073 
Phone: 248.551.9295 
Email: Kim.Killinger@beaumont.org 
 
 
1 This is the author manuscript accepted for publication and has undergone full peer review but has not been through 
the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this 
version and the Version of Record. Please cite this article as doi:10.1002/nau.23356 
 
Au
tho
r M
an
us
cri
pt
This article is protected by copyright. All rights reserved. 
 
Abstract word count:  249  
 
Manuscript word count: 2,423 
 
Keywords:  Urinary Bladder, Overactive; Implantable Neurostimulators; Depressive Symptoms  
 
Disclosures: A single co-author reports personal fees from Medtronic, outside the submitted 
work. The primary author and all other co-authors have nothing to disclose.  
 
Acknowledgement 
Funding: Philanthropy-Ministrelli Program for Urology Research and Education 
(MPURE) 
 
Kim A. Killinger1,2, Jonathan Fergus2, Luke Edwards1, Judith A. Boura1, 2, Jamie Bartley1,2, 
Priyanka Gupta3, Janice Tomakowsky1, Jason Gilleran1, 2, Kenneth M. Peters1, 2 
1Beaumont Health, Royal Oak, MI 
2Oakland University William Beaumont School of Medicine, Rochester, MI 
3 University of Michigan, Department of Urology, Ann Arbor, MI 
 
Corresponding Author: Kim A. Killinger, Beaumont, Royal Oak, 3535 West 13 Mile Road Ste. 
438, Royal Oak, MI 48073, Phone: 248.551.9295, Email: Kim.Killinger@beaumont.org 
 
Abstract word count: 249 
 
Manuscript word count: 2,423 
 
Keywords: Urinary Bladder, Overactive; Implantable Neurostimulators; Depressive Symptoms 
 
Disclosures: A single co-author reports personal fees from Medtronic, outside the submitted 
work. The primary author and all other co-authors have nothing to disclose. 
 
Acknowledgement 
Funding: Philanthropy-Ministrelli Program for Urology Research and Education (MPURE) 
Au
tho
r M
an
us
cri
pt
This article is protected by copyright. All rights reserved. 
 
Kim A. Killinger1,2, Jonathan Fergus2, Luke Edwards1, Judith A. Boura1, 2, Jamie 
Bartley1,2, Priyanka Gupta3, Janice Tomakowsky1, Jason Gilleran1, 2, Kenneth M. Peters1, 2 
1Beaumont Health, Royal Oak, MI 
2Oakland University William Beaumont School of Medicine, Rochester, MI 
3 University of Michigan, Department of Urology, Ann Arbor, MI 
 
Corresponding Author: 
Kim A. Killinger 
Beaumont, Royal Oak 
3535 West 13 Mile Road Ste. 438 
Royal Oak, MI 48073 
Phone: 248.551.9295 
Email: Kim.Killinger@beaumont.org 
 
Abstract word count: 249 
 
Manuscript word count: 2,423 
 
Keywords: Urinary Bladder, Overactive; Implantable Neurostimulators; Depressive Symptoms 
 
Disclosures: A single co-author reports personal fees from Medtronic, outside the submitted 
work. The primary author and all other co-authors have nothing to disclose. 
 
Au
tho
r M
an
us
cri
pt
This article is protected by copyright. All rights reserved. 
 
Acknowledgement 
Funding: Philanthropy-Ministrelli Program for Urology Research and Education 
(MPURE) 
 
Kim A. Killinger1,2, Jonathan Fergus2, Luke Edwards1, Judith A. Boura1, 2, Jamie 
Bartley1,2, Priyanka Gupta3, Janice Tomakowsky1, Jason Gilleran1, 2, Kenneth M. Peters1, 2 
1Beaumont Health, Royal Oak, MI 
2Oakland University William Beaumont School of Medicine, Rochester, MI 
3 University of Michigan, Department of Urology, Ann Arbor, MI 
 
Corresponding Author: 
Kim A. Killinger 
Beaumont, Royal Oak 
3535 West 13 Mile Road Ste. 438 
Royal Oak, MI 48073 
Phone: 248.551.9295 
Email: Kim.Killinger@beaumont.org 
 
Abstract word count: 249 
 
Manuscript word count: 2,423 
 
Keywords: Urinary Bladder, Overactive; Implantable Neurostimulators; Depressive Symptoms 
Au
tho
r M
an
us
cri
pt
This article is protected by copyright. All rights reserved. 
 
Disclosures: A single co-author reports personal fees from Medtronic, outside the submitted 
work. The primary author and all other co-authors have nothing to disclose. 
 
Acknowledgement 
Funding: Philanthropy-Ministrelli Program for Urology Research and Education 
(MPURE) 
 
ABSTRACT 
Aims: To examine the relationship between coexisting depressive symptoms and outcomes after 
staged neuromodulation procedures for refractory urological symptoms. 
Methods: Adults who enrolled in a prospective database and completed a Personal Health 
Questionnaire Depression Scale (PHQ-8) at baseline were reviewed. The PHQ-8 and 
Generalized Anxiety Disorder (GAD-7) assessed depressive/anxiety symptoms pre and 6 months 
post device implant. Urological symptoms were assessed with The Interstitial Cystitis Symptom 
Index/Problem Index (ICSI-PI) and Overactive Bladder Questionnaire (OAB-q) at baseline, 3 
and 6 months, and Global Response Assessments (GRA) post implant. Subjects, grouped by 
PHQ <10 and PHQ ≥10, were compared with Pearson’s Chi-square, Fisher’s Exact or Wilcoxon 
rank test, and Spearman’s correlations. 
Results: In 117 PHQ <10 and 84 PHQ ≥10 patients, age differed (mean 59 vs. 52 years; 
p=0.001), and PHQ <10 had lower GAD-7, ICSI-PI and OAB-q scores at baseline (p<0.0001, 
p=0.0003 and p<0.0008 respectively). Implantation rates were similar between groups. 
Reoperation and complication rates within the first 6 months did not differ, similar proportions 
(majority) were improved on the GRA at each time point, and ICSI-PI and OAB-q scores 
improved significantly. PHQ scores only improved significantly for those with baseline PHQ 
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≥10. Baseline PHQ strongly correlated with GAD-7 at baseline and 6 months, and baseline ICSI-
PI. Change in PHQ positively correlated with the change in GAD-7, 6 month ICSI-PI, and 
change in ICSI-PI from baseline to 6 months. 
Conclusions: Coexisting depressive symptoms do not limit the efficacy of neuromodulation and 
PHQ improvements correlate with improved anxiety and bladder symptoms. 
 
INTRODUCTION 
Urinary symptoms can disrupt social, physical, occupational, sexual, and recreational 
activities and as a result, have significant negative impact on the psychological and social 
well-being of the affected individual. Sacral neuromodulation (InterStim®; Medtronic Inc, 
Minneapolis, MN) is a well-established therapeutic option for patients with refractory 
overactive bladder (OAB) who have failed behavioral modification, pelvic floor 
rehabilitation, and anticholinergic therapy.1 Although sacral neuromodulation is FDA 
approved for bladder and bowel symptoms, improvements can also be achieved by directly 
stimulating the pudendal nerves to increase afferent stimulation.2 Neuromodulation is a 
minimally invasive, reversible treatment that has a high rate of success and a low incidence 
of serious adverse events.3 It has been shown that successful therapies for urinary 
incontinence including neuromodulation improve quality of life.4 
 Thus, over the last decade, neuromodulation has become an attractive treatment 
option for patients with refractory urinary urgency, frequency, and urge incontinence. 
Although many groups have aimed to determine predictors of response to therapy, little is 
known about how coexisting depressive symptoms affect initial response to, or outcomes of, 
neuromodulation. Siegel et al. showed that neuromodulation for voiding symptoms can 
positively affect depression scores.4 On the other hand, Van Balken’s group found that 
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patients’ with poor mental health were prone to failing neuromodulation with percutaneous 
tibial nerve stimulation (PTNS).5 A review of the literature found that although coexisting 
depression and other affective disorders negatively impact response to medical therapy in a 
variety of disease processes,6 few have examined how depressive symptoms at baseline 
might affect response to chronic neuromodulation for bladder symptoms. Therefore, we 
explored the impact of coexisting depressive symptoms assessed by validated questionnaires 
on outcomes in over 200 patients undergoing neuromodulation for refractory urological 
symptoms. 
 
MATERIALS AND METHODS 
After receiving Institutional Review Board approval in 2004, all patients over 18 years of age 
that were scheduled for a staged InterStim® procedure at our large referral center were invited to 
enroll in a prospective, longitudinal, observational neuromodulation database study. Participants 
choosing to enroll (approximately 82 to 95% of eligible patients) completed questionnaires by 
mail at baseline (pre-treatment) and during follow-up until device explantation or voluntary 
withdrawal from the study. Telephone calls, and repeated mailings were conducted as needed in 
an attempt to obtain complete follow up data. Medical history and surgical data, and 
complications, reoperations, and reprogramming sessions after implant were obtained from 
reviewing participants’ medical records. In 2013, measures to evaluate depressive and anxiety 
symptoms at baseline and 6 months were added to the prospective study. This analysis represents 
a retrospective review of the patients enrolled in the database that completed the depression and 
anxiety measures prior to neuromodulation. 
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Some patients had office percutaneous nerve evaluation (PNE) to determine initial 
response to treatment, but the majority had a two-stage operative procedure, which has been 
previously described. Briefly, during the first procedure (Stage I), a tined quadripolar lead was 
implanted at either the sacral or, alternatively, the pudendal nerve and connected to an external 
programmable device. After testing the device for approximately two weeks as an outpatient, 
patients returned for a second procedure (Stage II). If voiding symptoms had improved by at 
least 50% on voiding diaries, an implantable pulse generator (IPG) was placed. If symptoms did 
not improve by this margin, then the lead was removed and the patient did not proceed to 
permanent implant. 
Outcomes during the first 6 months after implant were evaluated. Depressive symptoms 
and anxiety were assessed at baseline and 6 months post-implant with the Personal Health 
Questionnaire Depression Scale (PHQ-8) and the Generalized Anxiety Disorder (GAD-7) 
questionnaire. The PHQ-8 questionnaire is an 8-item validated depression scale that has been 
used as a screening tool in population based studies.7 PHQ scores are categorized as 5-9 (mild 
depressive symptoms), 10-14 (moderate), 15-19 (moderately severe), and ≥ 20 (severe 
depressive symptoms). The GAD-7 questionnaire is a 7-item validated scale to assess 
generalized anxiety disorder.8 Scores range from 0-21 with higher scores indicating a higher 
degree of anxiety and ≥10 has been identified as a reasonable cutoff for identifying anxiety8. 
When the prospective data collection study began in 2004, many of our patients were 
undergoing neuromodulation for urinary urgency, frequency, and nocturia associated with 
IC/BPS, so urinary symptoms were measured in all patients with the validated Interstitial Cystitis 
Symptom Index and Problem Index (ICSI-PI; composite scores range from 0-36 with higher 
scores indicating more severity/bother) pre-treatment, and at 3 and 6 months post IPG implant. In 
Au
tho
r M
an
us
cri
pt
This article is protected by copyright. All rights reserved. 
 
2009, the Overactive Bladder Questionnaire Short Form (OAB-q SF; validated in patients with 
OAB) was added to assess symptom severity (OAB-q ss) and health related quality of life (OAB-
q HRQOL). Overall improvement in symptoms was assessed with scaled Global Response 
Assessments (GRA) between Stage I and Stage II, as well as at 3 and 6 months post IPG implant. 
On the GRA, patients rated overall changes in symptoms on a 7-point scale as “markedly worse, 
moderately worse, mildly worse, same, slightly improved, moderately improved, or markedly 
improved.” Treatment responders were those that reported a moderate or marked improvement 
on the GRA. 
Subjects were grouped by baseline PHQ score <10 and ≥10 (suggesting major depressive 
symptoms) and compared using Pearson’s Chi-square, Fisher’s Exact or Wilcoxon rank test, and 
Spearman’s correlations at each separate time point. Within and between groups paired changes 
in patients that completed questionnaires at both baseline and 6 months were examined with Sign 
tests. A p-value of <0.05 was considered statistically significant. All analyses used the SAS® 
System for Windows® (version 9.3, SAS Institute, Inc., Cary, NC). 
 
RESULTS 
Most patients in this longitudinal database study had enrolled prior to adding the PHQ-8 
questionnaire. Therefore, of 937 patients in the database, only 201 (21.5%) with complete 
baseline PHQ-8 questionnaire data were selected for inclusion. Of those included, most were 
female (173/201; 86.1%), Caucasian (87.6%), mean age was 56.0 ± 16.3 years, and mean body 
mass index (BMI) was 28.7 ± 7.1. Primary indications for neuromodulation varied and reflected 
our clinical population: overactive bladder (n = 91; 67 wet, 24 dry), pelvic pain without an 
interstitial cystitis/bladder pain syndrome (IC/BPS) diagnosis (n = 42), idiopathic urinary 
Au
tho
r M
an
us
cri
pt
This article is protected by copyright. All rights reserved. 
 
retention (n = 30), voiding and pelvic pain symptoms related to IC/BPS (n = 28), fecal 
incontinence (n=3), and neurological condition (n = 7). On the PHQ-8 at baseline, 84 subjects 
had symptoms of major depression (PHQ scores ≥10) and of these 84 subjects, 19 subjects had 
scores suggestive of severe major depression (score ≥ 20). 
When patients with PHQ <10 were compared to those with PHQ score ≥10, mean age 
was significantly different (59 ± 17 vs. 52 ± 15 years; p=0.001) but other demographics, initial 
success leading to IPG implantation, and operative characteristics did not differ between groups 
(Table 1). Since depressive and anxiety symptoms often coexist, it is not surprising that those 
with lower PHQ (<10) also had significantly lower scores on the GAD-7 at baseline (median 4 
vs. 13; p<0.0001) and 6 months (median 1 vs. 8; p<0.0001) (Table 2). For those subjects that had 
both baseline and 6 month data, GAD-7 scores only improved significantly in the PHQ <10 
group (n=49; p=0.01) and on the PHQ, only those in the PHQ ≥ 10 group had statistically 
significant improvement (n=30; p=0.013) (Table 2). Interestingly, the overall mean PHQ score in 
the PHQ ≥10 group improved enough to move from the “moderately severe depressive 
symptoms” into the “moderate” category. 
Table 3 illustrates changes in urological symptoms after neuromodulation. At baseline, 
the PHQ < 10 group had statistically significantly lower composite ICSI-PI (p=0.0003) and 
OAB-q ss scores (p=0.0008) compared to PHQ ≥ 10. In patients with data for both baseline and 
6 months measures, ICSI-PI and OAB-q ss scores improved over time (p<0.0001 for both 
groups). Similarly, the PHQ <10 group had significantly better OAB-q HRQOL scores at 
baseline (p<0.0001) and both PHQ groups improved over time (p=0.005 and p<0.0001 
respectively). On the GRA, similar proportions (≥ 50 % at each time point) in both groups had 
improved at 2 weeks after lead placement, and at 3 and 6 months. We used Spearman 
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correlations to examine baseline PHQ-8 scores, and the change in PHQ score between baseline 
and 6 months, to determine correlations with GAD-7 and ICSI-PI scores. The total PHQ-8 at 
baseline was strongly correlated with the baseline GAD-7 (r = 0.74; p<0.0001), the 6 month 
GAD-7 score (r=0.62; p<0.0001) and the baseline total ICSI-PI score (r=0.29; p<0.0001) but not 
correlated with the change in GAD-7, the 6 month total ICSI-PI score or the change in total 
ICSI-PI score. The change in total PHQ-8 score (between baseline and 6 months) was somewhat 
negatively correlated with the baseline total GAD-7 (r= -0.34; p=0.0017), but correlated 
positively with the change in GAD-7 score (r=0.55; p<0.0001), the ICSI-PI score at 6 months 
(r=0.33; p=0.0025) and the change in ICSI-PI score (r=0.33; p=0.0027). These correlations 
provide further evidence of association between depressive and anxiety symptoms, and their 
impact on problematic bladder symptoms. 
Although the primary focus of the study was to examine the impact of depressive 
symptoms on neuromodulation outcomes, we also compared patients grouped by GAD score <10 
and ≥ 10 (Table 4). Similar to the analysis of patients grouped by PHQ-8 scores, IPG 
implantation rate did not differ, but signific ntly fewer complications were seen in those with 
lower anxiety scores (GAD <10) (p=0.018). Not surprisingly, the GAD < 10 group had lower 
baseline PHQ-8 (p<0.0001), ICSI-PI (p=0.0004) and OAB-q SS (p=0.004) scores, and higher 
OAB-q HRQOL scores (p<0.0001). Although PHQ scores only decreased significantly in the 
GAD ≥ 10 group (p=0.036), both groups demonstrated significant improvements over time on 
the ICSI-PI, OAB-q SS and OAB-q HRQOL measures. 
 
Discussion 
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Concomitant affective disorders, particularly depression, have been shown to affect outcomes, 
complications, and response to treatment.6,9,10 Yet, little is known about the impact on 
neuromodulation outcomes even though depressive symptoms are associated with bladder 
symptoms.11 Burg et al. dichotomized patients undergoing coronary artery bypass grafting based 
on preoperative depression scores and found that depression was a significant predictor of 
hospitalization, ongoing pain, and failure to return to previous activity levels, all at 6 months post 
operatively.10 In a study of psychosocial factors related to neuromodulation use, Levin et al. 
demonstrated significant improvements in depression after treatment but did not evaluate 
whether baseline depression predicted overall outcomes.12 Another group found that patients 
with poor mental health were more prone to failing neuromodulation treatment for overactive 
bladder with percutaneous tibial nerve stimulation (PTNS).5 More recently, 86 men and women 
with OAB or non-obstructive urinary retention were retrospectively studied to explore the impact 
of anxiety and depression on neuromodulation response.13 Conducted in Europe, the study 
examined the relationship between baseline depressive/anxiety symptoms assessed with the 
Hospital Anxiety and Depression Scale, voiding diaries and urodynamics, and neuromodulation 
response initially and at 1 year.13 Similar to the results reported here, there was no significant 
relationship between abnormal depressive/anxiety symptom scores and failure to respond to 
neuromodulation. However, the study did not evaluate changes in depressive/anxiety or 
urological symptom outcomes over time. 
We sought to examine whether depressive symptoms as measured by PHQ-8 would 
portend any change in symptom response, outcomes, or complications over the short term after 
neuromodulation therapy. This study did not demonstrate an inferior response to 
neuromodulation among patients exhibiting major depressive symptoms (PHQ-8 scores ≥10). It 
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is worth noting that at baseline, those with PHQ-8 scores ≥10 had significantly higher ICSI-PI 
and OAB-q ss scores suggesting a higher level of initial urinary bother. This is not surprising 
since OAB has been associated with affective symptoms,11 and OAB patients with depression 
report more severe urinary incontinence symptoms, greater bother and more impact on quality of 
life.14 Measuring the impact of neuromodulation on depressive symptoms was not the aim of this 
study, but depressive symptoms did decrease significantly over 6 months after neuromodulation 
in those with PHQ-8 scores ≥10 at baseline. Although interesting, this finding may be due to the 
fact that significant decreases in scores are likely more probable in those that have more room for 
improvement (higher baseline scores). Also, the similar outcomes in patients when examine 
categorized by PHQ and GAD scores separately highlights the known association between 
depressive and anxiety symptoms. Even though patients undergoing neuromodulation for OAB 
may have coexisting depression and/or anxiety, and poor mental health has been shown to 
negatively influence response to neuromodulation with PTNS5, our results suggest that pre-
existing or concomitant depressive symptoms may not limit the therapeutic benefits of 
neuromodulation with an implanted device. 
In addition to symptom improvements, complications, reoperations, and device 
explantations are also outcomes important to both clinicians and patients. Overall, lower 
reoperation and complication rates were found in this study compared to some other published 
results.3 These findings may be attributable to differences in length of follow-up or definitions of 
reoperations or complications. Even though our data did not suggest that patients with depressive 
symptoms have higher complication or reoperation rates, we only evaluated these outcomes over 
6 months and longer follow-up may reveal differences between groups. Notwithstanding, 
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achieving symptom improvements to justify device implant and improve quality of life while 
avoiding complications or reoperation, are key goals for both patients and clinicians. 
Strengths of our study include sample size, use of validated questionnaires, and the 
prospective collection of pre and post implant data, which also enabled the study of changes in 
affective and urinary symptoms over time. Limitations include a potential for selection bias since 
not all patients undergoing neuromodulation elected to enroll in our prospective data collection 
study. Additionally, not all patients returned questionnaires at every time point and it is possible 
that not all complications were captured if treated outside our institution. The questionnaires 
used in this study captured changes in symptoms for the most common neuromodulation 
indications at our center, however future studies might examine other less common indications 
with condition specific validated measures. Our study sample was predominantly women and 
patients presented with a variety of voiding/storage symptoms, which is representative of our 
clinical population undergoing neuromodulation. Even though the site of lead placement 
(pudendal or sacral) and indications for neuromodulation varied, it is unlikely that these 
differences influenced outcomes since these data did not differ significantly between groups. 
 
Conclusion 
This study suggests that coexisting depressive symptoms do not limit the efficacy 
or therapeutic benefits of neuromodulation for refractory bladder symptoms over 
the short term. As such, depressive symptoms should not preclude neuromodulation 
device placement in appropriately selected patients and it is reasonable to 
expect similar outcomes for these patients. Future studies might more fully 
explore changes in psychological symptoms after neuromodulation as well as 
outcomes over the long term. 
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Table Legends: 
Table 1 
* within the first 6 months 
OAB: Overactive Bladder 
UUI: urinary urge incontinence 
IPG: implantable pulse generator 
PNE: percutaneous nerve evaluation 
Table 2 
GAD-7: Generalized Anxiety Disorder Questionnaire 
PHQ-8: Personal Health Questionnaire Depression Scale 
  *Only in patients with both baseline and 6 month data 
NT: Not tested 
Table 3 
*Only in patients with both baseline and 6 month data 
ICSI-PI: Interstitial Cystitis Symptom and Problem Index 
OAB-q: Overactive Bladder Questionnaire 
HRQOL: Health related quality of life 
Table 4 
IPG: implantable pulse generator 
*Only in patients with both baseline and 6 month data 
PHQ-8: Personal Health Questionnaire Depression Scale 
ICSI-PI: Interstitial Cystitis Symptom and Problem Index 
OAB-q: Overactive Bladder Questionnaire 
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HRQOL: Health related quality of life 
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Table 1. Descriptive Statistics 
 PHQ <10 
N=117 
PHQ ≥10 
N=84 
P value 
Primary Indication   0.59 
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  Fecal Incontinence 
  IC/PBS 
  Neurological Condition 
  OAB dry 
  OAB with UUI 
  Pelvic Pain 
  Retention 
2 (1.7%) 
16 (13.7%) 
5 (4.3%) 
15 (12.8%) 
43 (36.8%) 
19 (16.2%) 
17 (14.5%) 
1 (1.2%) 
12 (14.3%) 
2 (2.4%) 
9 (10.7%) 
24 (28.6%) 
23 (27.4%) 
13 (15.5%) 
Stage 1 operative time (minutes) 
 Median (25th, 75th) 
 Min to Max 
 
45 (35, 59) 
22 to 149 
 
43 (33, 54) 
19 to 110 
 
0.40 
Lead Location 
  Pudendal Lead 
  Sacral Lead 
 
54 (46.2%) 
63 (53.9%) 
 
38 (45.2%) 
46 (54.8%) 
 
0.90 
Office PNE 15/110 (13.6%) 6/82 (7.3%) 0.17 
IPG implant 96 (82.1%) 76 (90.5%) 0.09 
After IPG implant:  N=96 N=76  
 Number of Reprogrammings*  
 0 
 1 
 2 
 3 
 
77 (80.2%) 
18 (18.8%) 
0 
1 (1.0%) 
 
60 (79.0%) 
13 (17.1%) 
2 (2.6%) 
1 (1.3%) 
 
0.58 
 Number of Reoperations* 
 0 
 1 
 
87 (90.6%) 
9 (9.4%) 
 
71 (93.4%) 
5 (6.6%) 
 
0.51 
 Number of Complications* 
 0 
 1 
 2 
N=95 
86 (90.5%) 
8 (8.4%) 
1 (1.1%) 
 
63 (82.9%) 
12 (15.8%) 
1 (1.3%) 
 
0.27 
 
Table 2. GAD-7 and PHQ-8 Scores 
 PHQ <10 
N=117 
 PHQ ≥10 
N=84 
P value 
GAD-7 Median (25th, 75th) 
Min to Max 
Median (25th, 75th) 
Min to Max 
 
 Baseline 
  
4 (1, 9) 
0 to 17 
13 (8, 19) 
0 to 21 
<0.0001 
 6 Months 
 
 
N=49 
1 (0, 5) 
0 to 18 
N=31 
8 (5, 18) 
0 to 21 
<0.0001 
 Change between baseline and 6 
months 
  
N=49 
0 (-3, 0) 
-11 to 15 
N=31 
-2 (-8, 3) 
-21 to 11 
0.64 
 Change within groups * p=0.01  p=0.18   
PHQ-8 Mean ± SD (Median) 
Min to Max 
Mean ± SD (Median) 
Min to Max 
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 Baseline  4.3 ± 3.1 (4.0) 
0 to 9 
15.8 ± 4.1 (15) 
10 to 24 
 
NT 
 6 Months 
 
 
N=50 
3.6 ± 3.6 (2.5) 
0 to 15 
N=30 
12.3 ± 6.2 (12) 
0 to 23 
 
NT 
 
 Change between baseline and 6 
months 
  
N=50 
-0.2 ± 3.8 (-0.5) 
-8 to 10 
N=30 
-3.3 ± 6.4 (-2.5) 
-20 to 9 
 
NT 
 Change within groups * p=0.15  p=0.013   
 
Table 3. Urological Symptom Measures 
 PHQ <10 
N=117 
PHQ ≥10 
N=84 
P 
value 
ICSI-PI Score Mean ± SD 
(median) 
Mean ± SD 
(median) 
 
 Baseline 
 
N=116 
20 ± 7.5 (20) 
N=84 
24 ± 8.6 (26) 
0.0003 
 3 months 
 
N=62 
13 ± 7.4 (12) 
N=42 
14 ± 8.1 (13) 
0.36 
 6 months 
 
N=51 
14 ± 7.7 (13) 
N=32 
13 ± 7.8 (12) 
0.82 
 Change between baseline and 
6 months 
N=51 
-7.6 ± 7.9 (-6) 
N=32 
-10.2 ± 7.8 (-10) 
 
0.10 
 Change within groups * p<0.0001  p<0.0001   
OAB-q Symptom Severity Score Median (25th,75th) Median (25th,75th)  
 Baseline 
 
n=115 
50 (30, 67) 
n=84 
67 (42, 87) 
0.0008 
 3 months 
 
n=64 
23 (13, 53) 
n=42 
27 (13, 50) 
0.86 
 6 months 
 
n=51 
30 (10, 63) 
n=32 
22 (15, 47) 
0.48 
 Change between baseline and 
6 months 
n=51 
-17 (-37, -3.3) 
n=32 
-28 (-48, -10) 
0.13 
 Change within groups * P<0.0001 P<0.0001  
OAB-q HRQOL Score Median (25th,75th) Median (25th,75th)  
 Baseline 
 
n=115 
58 (35, 72) 
n=84 
29 (18, 56) 
<0.0001 
 3 months 
 
n=64 
79 (61, 94) 
n=41 
77 (49, 91) 
0.40 
 6 months 
 
n=51 
82 (42, 93) 
n=32 
76 (56, 92) 
0.87 
 Change between baseline and 
6 months 
n=51 
15 (-3.3, 35) 
n=32 
30 (9.2, 45) 
0.051 
 Change within groups * P=0.005 P<0.0001  
Global Response Assessments    
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(Moderately/Markedly Improved) 
 Between Stages I and II 55/81 (67.9%) 49/60 (81.7%) 0.066 
 3 months 36/64 (56.3%) 21/42 (50%) 0.53 
 6 months  28/51 (54.9%) 21/32 (65.6%) 0.33 
 
Table 4. Comparison of Patients Grouped by Baseline GAD score 
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 GAD < 10 
N=119 
GAD ≥ 10 
N=82 
 
P value 
IPG implant 98 (82.4%) 74 (90.2%) 0.12 
After IPG implant:     
 Number of Reoperations 
 0 
 1 
n=98 
91 (92.9%) 
7 (7.1%) 
n=74 
67 (90.5%) 
7 (9.5%) 
0.58 
 Number of Complications 
 0 
 1 
 2 
n=98 
91 (92.9%) 
7 (7.1%) 
0 
n=73 
58 (79.5%) 
13 (17.8%) 
2 (2.7%) 
0.018 
PHQ-8 Median (25th,75th) Median (25th,75th)  
 Baseline 
 
n=119 
5 (2, 9) 
n=82 
15 (9, 18) 
<0.0001 
 6 months 
 
n=50 
3 (1, 6) 
n=30 
11.5 (5, 18) 
<0.0001 
 Change between baseline and 6 
months 
n=50 
-1 (-2, 1) 
n=30 
-2.5 (-8, 1) 
0.047 
 Change within groups * P=0.08 P=0.036  
ICSI-PI Score Mean ± SD 
(median) 
Mean ± SD 
(median) 
 
 Baseline 
 
n=118 
19.5 ± 8.0 (19.5) 
n=82 
23.5 ± 8.0 (25) 
0.0004 
 3 months 
 
n=63 
13.0 ± 7.6 (11) 
n=41 
13.7 ± 7.8 (12) 
0.67 
 6 months 
 
n=50 
12.9 ± 8.2 (12) 
n=33 
14.2 ± 6.9 (13) 
0.41 
 Change between baseline and 6 
months 
n=50 
-7.3 ± 7.1 (-6) 
n=33 
-10.5 ± 8.7 (-10) 
0.08 
 Change within groups * P<0.0001 P<0.0001  
Global Response Assessments 
(Moderately/Markedly Improved) 
 
n (%) 
 
n (%) 
 
 Between Stages 1 and 2 60/84 (71.4%) 44/57 (77.2%) 0.45 
 3 months 36/64 (56.3%) 21/42 (50.0%) 0.53 
 6 months  28/50 (56.0%) 21/33 (63.6%) 0.49 
OAB-q Symptom Severity Score Median (25th,75th) Median (25th,75th)  
 Baseline 
 
n=118 
50 (27, 70) 
n=81 
63 (43, 83) 
0.004 
 3 months 
 
n=64 
23 (13, 53) 
n=42 
25 (13, 47) 
0.55 
 6 months 
 
n=50 
28 (13, 63) 
n=33 
23 (17, 50) 
0.88 
 Change between baseline and 6 
months 
n=50 
-19 (-33, -3.3) 
n=33 
-27 (-50, -10) 
0.15 
 Change within groups * P<0.0001 P<0.0001  
OAB-q HRQOL Score Median (25th,75th) Median (25th,75th)  
 Baseline 
 
n=118 
58 (32, 74) 
n=81 
32 (18, 57) 
<0.0001 
 3 months 
 
n=64 
81 (61, 94) 
n=41 
77 (40, 88) 
0.21 
 6 months 
 
n=50 
82 (42, 95) 
n=33 
75 (54, 85) 
0.34 
 Change between baseline and 6 
months 
n=50 
13 (-3.1, 34) 
n=33 
31 (14, 48) 
0.018 
 Change within groups * P=0.004 P<0.0001  
